Mapping the structural requirements in the CB1 cannabinoid receptor transmembrane helix II for signal transduction

Journal of Pharmacology and Experimental Therapeutics

Volumn 325, Issue 1, 2008, Pages 341-348

  Kapur, Ankur ^a   Samaniego, Patrick ^a   Thakur, Ganesh A ^b   Makriyannis, Alexandros ^b   Abood, Mary E ^a  

^a CALIFORNIA PACIFIC MEDICAL CENTER   (United States)

^b NORTHEASTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 (2,4 DICHLOROPHENYL) 5 (4 IODOPHENYL) 4 METHYL N MORPHOLINO 1H PYRAZOLE 3 CARBOXAMIDE; 11BETA HYDROXY 3 (1',1' DIMETHYLHEPTYL)HEXAHYDROCANNABINOL; 2,3 DIHYDRO 5 METHYL 3 (MORPHOLINOMETHYL) 6 (1 NAPHTHOYL)PYRROLO[1,2,3 DE][1,4]BENZOXAZINE; 4 (1,1 DIMETHYLHEPTYL) 1',2',3',4',5',6' HEXAHYDRO 2,3' DIHYDROXY 6' (3 HYDROXYPROPYL)BIPHENYL; AM 4056; ASPARAGINE; ASPARTIC ACID; CANNABINOID 1 RECEPTOR; CANNABINOID 1 RECEPTOR AGONIST; CANNABINOL DERIVATIVE; DEXANABINOL; GLUTAMIC ACID; GUANOSINE 5' O (3 THIOTRIPHOSPHATE); ISOLEUCINE; LIGAND; MUTANT PROTEIN; RIMONABANT; UNCLASSIFIED DRUG;

AMINO ACID SUBSTITUTION; ARTICLE; CELL STRAIN HEK293; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG POTENCY; DRUG RECEPTOR BINDING; EMBRYO; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN FUNCTION; RECEPTOR AFFINITY; SIGNAL TRANSDUCTION; SITE DIRECTED MUTAGENESIS; WILD TYPE;

AMINO ACID SUBSTITUTION; ASPARAGINE; BINDING SITES; CONSERVED SEQUENCE; HUMANS; PROTEIN BINDING; PROTEIN STRUCTURE, SECONDARY; RECEPTOR, CANNABINOID, CB1; SEQUENCE ALIGNMENT; SIGNAL TRANSDUCTION;

EID: 41149089767     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.107.133256     Document Type: Article

References (36)

1. Adan RA, Tiesjema B, Hillebrand JJ, la Fleur SE, Kas MJ, and de Krom M (2006) The MC4 receptor and control of appetite. Br J Pharmacol 149:815-827.
2. Ballesteros JA and Weinstein H (1995) Integrated methods for the construction of three dimensional models and computational probing of structure function relations in G protein-coupled receptors, in Methods in Neuroscience (Conn PM and Sealfon SM eds) pp 366-428, Academic Press, San Diego.
3. 35S]GTPγS binding to rat cerebellar membranes correlates with agonist-induced decreases in GDP affinity. J Biol Chem 273:16865-16873.
4. Brelot A, Heveker N, Montes M, and Alizon M (2000) Identification of residues of CXCR4 critical for human immunodeficiency virus coreceptor and chemokine receptor activities. J Biol Chem 275:23736-23744.
5. Chabot DJ, Zhang PF, Quinnan GV, and Broder CC (1999) Mutagenesis of CXCR4 identifies important domains for human immunodeficiency virus type 1 X4 isolate envelope-mediated membrane fusion and virus entry and reveals cryptic coreceptor activity for R5 isolates. J Virol 73:6598-6609.
6. Cheng YC and Prusoff WH (1973) Relationship between the inhibition constant (Ki) and the concentration of inhibitor which causes 50 percent inhibition (IC50) on an enzymatic reaction. Biochem Pharmacol 22:3099-3108.
7. 1 T210 produce active and inactive receptor forms: correlations with ligand affinity, receptor stability, and cellular localization. Biochemistry 45:5606-5617.
8. D'Antona AM, Ahn KH, Wang L, Mierke DF, Lucas-Lenard J, and Kendall DA (2006b) A cannabinoid receptor 1 mutation proximal to the DRY motif results in constitutive activity and reveals intramolecular interactions involved in receptor activation. Brain Res 1108:1-11.
9. Després JP (2007) The endocannabinoid system: a new target for the regulation of energy balance and metabolism. Crit Pathw Cardiol 6:46-50.
10. Fan W, Voss-Andreae A, Cao WH, and Morrison SF (2005) Regulation of thermogenesis by the central melanocortin system. Peptides 26:1800-1813.
11. Farooqi IS, Keogh JM, Yeo GS, Lank EJ, Cheetham T, and O'Rahilly S (2003) Clinical spectrum of obesity and mutations in the melanocortin 4 receptor gene. N Engl J Med 348:1085-1095.
12. Fay JF, Dunham TD, and Farrens DL (2005) Cysteine residues in the human cannabinoid receptor: only C257 and C264 are required for a functional receptor, and steric bulk at C386 impairs antagonist SR141716A binding. Biochemistry 44:8757-8769.
13. Howlett AC, Barth F, Bonner TI, Cabral G, Casellas P, Devane WA, Felder CC, Herkenham M, Mackie K, Martin BR, et al. (2002) International Union of Pharmacology. XXVII. Classification of cannabinoid receptors. Pharmacol Rev 54:161-202.
14. Huszar D, Lynch CA, Fairchild-Huntress V, Dunmore JH, Fang Q, Berkemeier LR, Gu W, Kesterson RA, Boston BA, Cone RD, et al. (1997) Targeted disruption of the melanocortin-4 receptor results in obesity in mice. Cell 88:131-141.
15. Johns DG, Behm DJ, Walker DJ, Ao Z, Shapland EM, Daniels DA, Riddick M, Dowell S, Staton PC, Green P, et al. (2007) The novel endocannabinoid receptor GPR55 is activated by atypical cannabinoids but does not mediate their vasodilator effects. Br J Pharmacol 152:825-831.
16. Kapur A, Hurst DP, Fleischer D, Whitnell R, Thakur GA, Makriyannis A, Reggio PH, and Abood ME (2007) Mutation studies of Ser7.39 and Ser2.60 in the human CB1 cannabinoid receptor: evidence for a serine-induced bend in CB1 transmembrane helix 7. Mol Pharmacol 71:1512-1524.
17. Kjelsberg MA, Cotecchia S, Ostrowski J, Caron MG, and Lefkowitz RJ (1992) Constitutive activation of the alpha 1B-adrenergic receptor by all amino acid substitutions at a single site. Evidence for a region which constrains receptor activation. J Biol Chem 267:1430-1433.
18. Lubrano-Berthelier C, Durand E, Dubern B, Shapiro A, Dazin P, Weill J, Ferron C, Froguel P, and Vaisse C (2003) Intracellular retention is a common characteristic of childhood obesity-associated MC4R mutations. Hum Mol Genet 12:145-153.
19. Matsuda LA, Lolait SJ, Brownstein MJ, Young AC, and Bonner TI (1990) Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 346:561-564.
20. 1 receptor activation. J Biol Chem 279:48024-48037.
21. 1 receptor constitutes an agonist/inverse agonist binding region. J Med Chem 46:5139-5152.
22. Munro S, Thomas KL, and Abu-Shaar M (1993) Molecular characterization of a peripheral receptor for cannabinoids. Nature 365:61-65.
23. Nie J and Lewis DL (2001) The proximal and distal C-terminal tail domains of the CB1 cannabinoid receptor mediate G protein coupling. Neuroscience 107:161-167.
24. 1 receptor. Mol Pharmacol 68:1484-1495.
25. Roche J, Bounds S, Brown S, and Mackie K (1999) A mutation in the second transmembrane region of the CB1 receptor selectively disrupts G protein signaling and prevents receptor internalization. Mol Pharmacol 56:611-618.
26. Ryberg E, Larsson N, Sjogren S, Hjorth S, Hermansson NO, Leonova J, Elebring T, Nilsson K, Drmota T, and Greasley PJ (2007) The orphan receptor GPR55 is a novel cannabinoid receptor. Br J Pharmacol 152:1092-1101.
27. Schüller U, Koch A, Hartmann W, Garre ML, Goodyer CG, Cama A, Sorensen N, Wiestler OD, and Pietsch T (2005) Subtype-specific expression and genetic alterations of the chemokinereceptor gene CXCR4 in medulloblastomas. Int J Cancer 117:82-89.
28. 2A receptor. J Biol Chem 270:16683-16688.
29. Song Z-H and Bonner TI (1996) A lysine residue of the cannabinoid receptor is critical for receptor recognition by several agonists but not WIN55212-2. Mol Pharmacol 49:891-896.
30. 2, disrupts G-protein coupling. J Pharmacol Exp Ther 285:651-658.
31. Tao YX (2005) Molecular mechanisms of the neural melanocortin receptor dysfunction in severe early onset obesity. Mol Cell Endocrinol 239:1-14.
32. Tao YX and Segaloff DL (2005) Functional analyses of melanocortin-4 receptor mutations identified from patients with binge eating disorder and nonobese or obese subjects. J Clin Endocrinol Metab 90:5632-5638.
33. 2A-adrenergic receptor. Mol Pharmacol 59:532-542.
34. Wilson MH and Limbird LE (2000) Mechanisms regulating the cell surface residence time of the alpha 2A-adrenergic receptor. Biochemistry 39:693-700.
35. Xu W, Ozdener F, Li JG, Chen C, de Riel JK, Weinstein H, and Liu-Chen LY (1999) Functional role of the spatial proximity of Asp114(2.50) in TMH 2 and Asn332(7.49) in TMH 7 of the mu opioid receptor. FEBS Lett 447:318-324.
36. Zhou W, Flanagan C, Ballasteros JA, Konvica K, Davidson JS, Weinstein H, Millar RP, and Sealfon SC (1994) A reciprocal mutation supports helix 2 and helix 7 proximity in the gonadotropin-releasing hormone receptor. Mol Pharmacol 45: 165-170.